Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: Results of a phase I study

Gynecologic Oncology

Volumn 81, Issue 2, 2001, Pages 216-224

  Prince, H Miles ^a   Rischin, Danny ^a,b   Quinn, Michael ^b   Allen, David ^b   Planner, Robert ^b   Neesham, Deborah ^b   Gates, Priscilla ^a   Davison, Jill ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

Carboplatin; High dose therapy; Ovarian cancer; Paclitaxel; Topotecan

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CD34 ANTIGEN; DEXAMETHASONE; PACLITAXEL; PENTETATE TECHNETIUM TC 99M; PROMETHAZINE; RANITIDINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT GM; DRUG INDUCED DISEASE; DRUG MEGADOSE; FEMALE; GYNECOLOGIC CANCER; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0035015610     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6121     Document Type: Article

References (63)

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
2. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel
3. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer
4. Sequences of topotecan and cisplatin: A phase I, pharmacologic, and in vitro studies to examine sequence dependence
5. Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma
6. Phase I study of topotecan and cisplatin in patients with advanced solid tumours: A cancer and leukemia group B study
7. Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer
8. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: A Gynecologic Oncology Group study
9. Topotecan and paclitaxel in extensive stage small cell lung cancer as initial therapy
10. Topotecan and paclitaxel, an active couplet, in untreated extensive disease small cell lung cancer
11. Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer
12. Toxicity of paclitaxel and topotecan with previously untreated extensive small cell lung cancer
13. A phase I/II and pharmacokinetic study of 96 hour infusional topotecan and paclitaxel chemotherapy for relapsed epithelial ovarian cancer
14. Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel and platinum resistant advanced ovarian cancer
15. Phase II trial of topotecan combined with cisplatin in squamous and non-squamous cervival cancer: Preliminary results
16. Phase I study of topotecan with carboplatin alternating with paclitaxel via a 3 hour infusion in combination with carboplatin in treatment of newly diagnosed ovarian cancer patients
17. A phase I study of carboplatin and escalating dose of topotecan in late recurrent ovarian carcinoma
18. Phase I study of topotecan plus carboplatin/paclitaxel in advance solid tumours
19. Back to the future: Multiagent chemotherapy in ovarian cancer revisited
20. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy
21. Reinfusion and serial measurements of carboplatin-mobilized peripheral-blood progenitor cell in patients receiving multiple cycles of high-dose chemotherapy
22. Rapid delivery of multiple courses of high-dose chemotherapy with granulocyte colony-stimulating factor and peripheral blood derived hematopoietic progenitor cells
23. Simultaneous dose-escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: A phase I trial
24. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: A phase I/II study in advanced ovarian cancer
25. Dose escalation of paclitaxel with high-dose carboplatin using peripheral blood progenitor cell support in patients with advanced ovarian cancer
26. Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer
27. High-dose chemotherapy in ovarian carcinaoma
28. Phase I clinical and pharmacokinetic study of high dose mitoxantrone combined with carboplatin, cyclophosphamide and autologous bone marrow rescue: High response rate for refractory ovarian carcinoma
29. Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer
30. Characteristics of cisdiaminedochloroplatinum (II)-resistant human ovarian cancer cell line and its evaluation in platinum analogues
31. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma
32. A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles
33. Randomised study of dose-intensity with single agent carboplatin in patients with epithelial ovarian cancer
34. Dose-effect study of carboplatin in ovarian cancer: A Danish Ovarian Cancer Group Study
35. A randomized trial of paclitaxel at 2 dose levels and filgrastim at 2 doses in platinum pretreated epithelial ovarian cancer: A Gynecologic Oncology Group, SWOG, NCCTG and ECOG study
36. Effect of P-glycoprotein expression on accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analog
37. In vitro and in vivo effects of clinically important camptothecin analogues in multidrug resistant cells
38. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer
39. Phase I and pharmacologic study of topotecan: A novel topoisomerase 1 inhibitor
40. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumours
41. Carboplatin dosing based on measurement of renal function-experience at the Peter MacCallum Cancer Institute
42. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
43. Peripheral blood CD34-positive cell count reliably predicts autograft yield
44. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens
45. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: A rational approach to clinical protocol design
46. Impact of carboplatin sequence on myelosuppression and systemic exposure of topotecan in small cell lung cancer
47. High-dose chemotherapy with autologous transplantation for persistant/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients
48. High-dose chemotherapy with hematopoietic rescue on patients with stage III to IV ovarian cancer: Long-term results
49. High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: A retrospective analysis of 35 patients treated in France
50. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell resuce in patients with advanced stage III/IV ovarian cancer
51. High dose combination chemotherapy and bone marrow rescue for ovarian carcinoma: Current status in the United States. Autologous marrow and blood transplantation
52. High-dose chemotherapy with autologous bone marrow transplantation in ovarian cancer. Autologous marrow and blood transplantation
53. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administerd intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer
54. Topotecan and high-dose cyclophosphamide: Salvage therapy for pediatric solid tumors
55. Phase I study of high-dose topotecan and alkylating agents for advanced ovarian cancer
56. Phase I/II trial of multicycle paclitaxel/carboplatin/topotecan/etoposide/thiotepa with peripheral blood progenitor support in ovarian cancer
57. Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer
58. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral blood stem cells
59. Phase I study of multiple cycles of high dose topotecan, carboplatin and paclitaxel with peripheral blood stem cell support
60. Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion
61. Phase I trial of topotecan administered by 24-hour infusion without and with G-CSF
62. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial
63. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group study